CA2021846A1 - Substituted benzoylurea compounds or their salts, processes for their production and antitumour compositions containing them - Google Patents
Substituted benzoylurea compounds or their salts, processes for their production and antitumour compositions containing themInfo
- Publication number
- CA2021846A1 CA2021846A1 CA002021846A CA2021846A CA2021846A1 CA 2021846 A1 CA2021846 A1 CA 2021846A1 CA 002021846 A CA002021846 A CA 002021846A CA 2021846 A CA2021846 A CA 2021846A CA 2021846 A1 CA2021846 A1 CA 2021846A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- compound
- alkyl group
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
Abstract
ABSTRACT
A substituted benzoylurea compound of the formula (I):
A substituted benzoylurea compound of the formula (I):
Description
202~84~
Our Ref.: IH-78 SUBSTITUTED BENZOYLUREA COMPOUNDS OR THEIR SALTS, PROCESSES FOR THEIR PRODUCTION AND ANTITUMOUR
COMPOSITIONS CONTAINING THEM
The present invention relates to novel substituted benzoylurea compounds or their salts, having an N-substituted benzoyl group on one side of the urea chain and a substituted pyrimidinyloxyphenyl group on the other side, processes for their production, intermediates thereof, compositions for treating a cancer such as leukemia, melanoma, sarcoma or carcinoma which comprise the substituted benzoylurea compounds or their salts, and a method for treating such a cancer.
Those similar to the substituted benzoylurea compounds of the present invention are disclosed in European Patent Publication No. 193249. However, the compounds of the present invention are different from them in the chemical structure with respect to the substituent bonded to the phenyl ring directly bonded to the urea group. Further, the compounds of the present invention are superior in the antitumour activities to 20218~6 the compounds disclosed in the above publication.
Further, European Patent Publication No. 335~08 discloses benzoylurea compounds. However, these compounds and the compounds of the present invention are different in the chemical structure with respect to the presence or absence of the substituent at the carbon atom or the nitrogen atom of the carbonylurea chain and with respect to the type of the substituent to the amino group as the substituent on the benzoyl group.
Further, the compounds of the present invention are superior to the conventional benzoylurea compounds in the solubility to a non-aqueous solvent.
The present inventors have found that the substituted benzoylurea compounds of the following formula (I) and their salts show a high level of antitumour activities, and they have an improved solubility in a non-aqueous solvent while the conventional benzoylurea compounds tend to be hardly soluble in a non-aqueous solvent. The present invention has been accomplished on the basis of these discoveries.
The present invention provides a substituted benzoylurea compound of the formula (I):
~ - CONHCONH
~21846 -wherein Rl is a hydrogen atom, a halogen atom or a nitro group, each of R2 and R3 is a hydrogen atom, an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 twherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt.
The present invention also provides processes for the production of the compound of the formula (I) or its salt, an intermediate thereof, a composition for treating a cancer such as leukemia, melanoma, sarcoma or carcinoma, which comprises the compound of the formula lI) or its salt, and a method for treating such a cancer.
Now, the present invention will be described in detail with reference to the preferred embodiments.
In the formula (I), the substituent of the substituted alkyl group, the substituted alkoxy group and the substituted alkylthio group in the definition of R4 includes, for example, a halogen atom, an alkoxy group, an alkylthio group, a cyano group, a thiocyanate group, an alkoxycarbonyl group, a carboxyl group and an alkylthiocarbonyl group. The substituent of the substituted alkyl group in the definition of R5 may be a 202~8~6 halogen atom. The number of substituents contained in R4 and R5 may be one or more.
The heterocyclic group formed by R2 an~ R3 together with the adjacent nitrogen atom, may be a morpholino group, an aziridinyl group, a pyrrolidinyl group, a piperidino group or a pyrrolyl group.
The salt of the benzoylurea compound of the present invention may be any salt so long as it is pharmaceutically acceptable. For example, it may be a salt of a hydrogen halide such as hydrochloric acid or hydrobromic acid, or a salt of an alkali metal such as sodium or potassium, or of an alkaline earth metal such as magnesium or calcium.
The halogen atom in the definition of Rl, R4 and R5, includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
In the formula (I), the alkyl moiety constituting the alkyl group and the alkoxy group in the definition of R2 and R3, the alkyl moiety constituting the substituted or unsubstituted alkyl group, the substituted or unsubstituted alkoxy group and the substituted or unsubstituted alkylthio group in the definition of R4, the alkyl moiety constituting the substituted or unsubstituted alkyl group in the deti.mition of R5, and 2S the alkyl moiety constituting the alkoxy group, the alkylthio group, the alkoxycarbonyl group or the alkylthio carbonyl group as the substituent of the 2021~6 substituted alkyl group, the substituted alkoxy group and the substituted alkylthio group in the definition of R4, is preferably an alkyl group having from 1 to 10 carbon atoms such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group or a decyl group, more preferably an alkyl group having from 1 to 4 carbon atoms. Further, these alkyl group also include linear or branched aliphatic chain structural isomers.
In the above formula (I), a substituted benzoylurea compound of the following formula (I') or its salt, is preferred:
~ 2 ~ -< ~ R5 (I ) N ~R R4 wherein Rl, R2, R3, R4 and R5 are as defined above.
Rl is preferably a hydrogen atom. Each of R2 and R3 is preferably an alkyl group. Also preferably, R2 and R3 form together with the adjacent nitrogen atom a heterocyclic ring. R4 iS preferably a halogen atom or a substituted or unsubstituted alkyl group, more preferably a substituted or unsubstituted alkyl group. R5 is preferably a halogen atom. The following compounds are preferred among the substituted benzoylurea compounds of the formula (I) and their salts:
. .
, N-[4-(5-bromo-2-pyrimidinyloxy)-3 methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea hydrochloride, N-[4-(5-bromo-2-pyrimidinyloxy)-3-trifluoromethylphenyl]-N'-[2-(dimethylamin~)benzoyl]urea, N-[4-(5-chloro-2-pyrimidinyloxy)-3-trifluoromethylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea, and N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea.
lS The benzoyl urea compound of the formula (I) can be prepared by the following methods:
(A) R
Hal ~ O ~ O } ~5 + HN < ~~~ (I
(II) (III) wherein Rl, R2, R3, R.4 and R5 are as defined above, and Hal is a halogen atom.
This reaction is conducted usually at a temperature of from 0C to a reflux temperature, and the reaction time is usually from 1 to 24 hours. A solvent may be used for this reaction. Such a solvent includes, for example, benzene, toluene, xylene, chlorobenzene, hexane, chloroform, methylene chloride, dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylsulfoxide, hexamethylphosphoric triamide, and water.
(B) R
10~ R2I ~ O ~ O } R
(IV) (V) Rl 5 ~~~ ~ - CONHCONH ~ ~ O } R5 (I-l) \ R3 R4 wh~rein Rl, R~ and R5 are as defined above, each of Al and A2 is -NCO or -NH2, provided that when Al is -NCO, A2 is -NH2, and when Al is -NH2, A2 is -NCO, and each of R2 and R3 is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring.
This reaction is conducted usually in the presence of a solvent at a temperature of from 0C to a reflux 2021~
temperature, and the reaction time is usually from 1 to 24 hours. The solvent includes, for example, benzene, toluene, xylene, chlorobenzene, hexane, chloroform, methylene chloride, dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylsulfoxide and hexamethylphosphoric triamide.
(C) ~ CONHCONH ~~N~ S hydr~zine N-Bl R4 ( VI ) (~ CONHCONH ~O --~ ~KS
( I - 2 ) wherein Rl, R4 and R5 are as defined above, and Bl is a phthaloyl group.
The hydrazine may be hydrazine, an alkyl hydrazine or phenyl hydrazine.
~ his reaction is conducted usually in the presence of a solvent at a temperature of from 0C to a reflux temperature, and the reaction time is usually from 1 to 24 hours. The solvent includes, for example, methanol, ethanol, chloroform, and methylene chloride.
-- 20218~6 (D) Rl l (C~ CONHCONH ~ ~\ ~--R5~ reduction IVII ) Rl l ~ CONHCONH ~O --~ (~--R5 \NH2 R4 ' ( I - 3 ) wherein Rl is a hydrogen atom or a halogen atom, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group or a substituted or unsubstituted alkylthio group, and R5 is a halogen atom or a substituted or unsubstituted alkyl group.
This reaction is conducted in accordance with a usual reduction method. The reduction method may, for example, be a redu~tion method using a metal such as reduced iron or zinc, or a catalytic reduction method using a catalyst such as platinum or palladium-carbon. The reaction is conducted usually at a temperature of from 0C to a reflux temperature, and the reaction time is usually from 1 to 100 hours.
( E ) Rl ~ CONHCONH <~ ~ O}R5 ~Ia1 R (VIII) (I-2) Rl <~ ~ R2 " ~-- N }
\H R4 (IX) wherein Rl, R4 and R5 are as defined above, and R2 is an alkyl group.
This reaction is conducted usually at a temperature of from 0C to a reflux temperature, and the reaction lS time is usually from 0.1 to 24 hours. A solvent and a base may be used for this reaction. The solvent includes, for example, benzene, toluene, xylene, chlorobenzene, pyridine, hexane, cyclohexane, chloroform, methylene chloride, dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylsulfoxide and hexamethylphosphoric triamide. The base includes an organic lithium such as n-butyl lithium, tert-butyl lithium or phenyl lithium, an inorganic base such as sodium hydroxide, potassium hydroxide, sodium hydride or ; potassium hydride, and an organic base such as triethylamine or pyridine.
- 20218~6 (F) ~/R2~ } 5 Ual - R3 (X) N\H R4 ( IX ) <~R3 ~ ~ ~O}R5 R3~
(XI) . wherein Rl, R2 , R4 and Rs are as defined above, and R3 is an alkyl group.
lS The reaction conditions may be the same as described above with respect to (E).
Eurther, the compounds of the formula (II) and (VII) can be prepared in accordance with the above method (B).
A compound of the formula (IV) wherein Al is -NH2, can be prepared, for example, by reacting a 2-halogenobenzamide with a secondary amine of the formula (III) in accordance with the above method (A), and a compound wherein Al is -NCO can be prepared by reacting the benzamide obtained by the above method, with oxalyl chloride at a temperature of from 0C to a reflux temperature for from 1 to 100 hours in the presence of the same solvent as mentioned in the above method (B). Further, a compound of the formula ~02~
(VI) can be prepared in accordance with the above method (B) by using either a benzamide obtained by reacting a ~-aminobenzamide with phthalic anhydride at a tempe~ature of from 0C to a reflux temperature for from l to lO0 hours in the presence of a solvent such as chloroform, methylene chloride or pyridine, or an isocyanate obtained by reacting the benzamide obtained by the above-mentioned method, with oxalyl chloride at a temperature of from 0C
to a refluxing temperature for 1 to lO0 hours in the presence of the same solvent as mentioned in the above method (B).
Further, the salt of the substituted benzoylurea compound can readily be obtained by a usual production method.
Among the compounds of the formula (IV), those wherein R2 and R3 are -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above) (as represented by the following formula (XII)) are novel. Among the compounds of the formula ~XII), those wherein Al is -NH2 are preferred.
Rl ~ -COAl (XII) N
wherein each of R2 and R3 is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or ` 2021846 -SO2R6 (wherein R6 is as defined above), provided that either one of R2 and R3 is -COR6 or -SO2R6, and and Al are as defined above.
Now, specific Preparation Examples of the compounds of the formula (I) will be described.
Preparation of N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoYl~urea (Compound No. 1 as described hereinafter) A solution of a mixture comprising 3.73 g of 4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl isocyanate, 2.0 g of 2-(dimethylamino)benzamide and 45 me of toluene, was reacted under reflux for 4 hours.
After completion of the reaction, the mixture was cooled, and insoluble substances were removed by filtration. The filtrate thereby obtained was concentrated and purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 6:4) to obtain 3.9 g of the desired product (melting point: 98 - 104C) (Compound No. 1 as described hereinafter).
PREPARAT~ON EXAMPLE 2 Preparation of N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenYl]-N'-[2-(dimethYlamino)benzoYl]urea hydrochloride (Compound No. 2 as described hereinafter) 1.5 g of the desired product obtained in Example 1 (Compound No. 1 as described hereinafter) was dissolved ~ .
' 20218~
in 20 me of diethyl ether and 50 me of methylene chloride, and hydrochloric acid gas was introduced to the solution and saturated therein.
Thereafter, the saturated solution was stirred for one hour and then cooled, and precipitated crystals were collected by filtration. The crystals thus obtained were washed with diethyl ether to obtain 1.55 g of the desired product (melting point: 117 - 123C) (Compound No. 2 as described hereinafter).
Preparation of N-(2-aminobenzoyl)-N'-[4-(5-bromo-2-PYrimidinYloxY)-3-chlorophenyl]urea (Compound No. 26 as described hereinafter) A mixture comprising 1.0 g of N-[4-(5-bromo-2-; 15 pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoyl)urea and 30 me of glacial acetic acid, was heated to 80C, and 0.57 g of reduced iron was gradually added thereto under stirring. Thereafter, the mixture was stirred and reacted at the same temperature for 30 minutes.
After completion of the reaction, the reaction mixture was poured into water, and the insoluble product was collected by filtration. ~he collected insoluble product was dxied under vacuum and purified by silica gel column chromatography ~developing solvent; n-hexane:ethyl acetate = 7:3) to obtain 0.4 g of the desired product (melting point: 196 - 200C) (Compound No. 26 as described hereinafter).
--- 202~8~6 Preparation of N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-(2-morpholinobenzoyl)urea (Compound No.
34 as described hereinafter) (1) 5 g of 2-fluorobenzamide and 25 me of morpholine were reacted in an autoclave at 100C for 18 hours.
After completion of the reaction, the reaction product was cooled, and excess morpholine was distilled off. The residue was purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 3:7) to obtain 2.8 g of 2-morpholinobenzamidé
(melting point: 112 - 119C).
(2) A solution obtained by dissolving 3.28 g of 4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl isocyanate in 30 me of toluene, was dropwise added to 2.21 g of 2-morpholinobenzamide obtained in the above step (1) under stirring. Thereafter, the mixture was reacted at 100C
for 3 hours.
After completion of the reaction, toluene was distilled off, and the residue was purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 1:1) to obtain 1.25 g of the desired product (melting point: 67 - 70C, amorphous) (Compound No. 34 as described hereinafter).
Preparation of N-[4-(5-chloro-2-pyrimidinyloxy)-3-methYlphenyl]-N'-[2-(dimethylamino)benzoyl]urea (Compound 202184~
No. 11 as described hereinafter) A solution of a mixture comprising 3.33 g of 4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl isocyanate, 2.1 g of 2-(dimethylamino)benzamide and 30 me of toluene, was reacted at 100C for 4 hours.
After completion of the reaction, the solution mixture was cooled, and insoluble substances were removed by filtration. The filtrate thereby obtained was concentrated and purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 6:4) to obtain 2.84 g of the desired product (melting point: 48 - 52C, amorphous) (Compound No. 11 as described hereinafter).
Preparation of N-[4-(5-bromo-2-pYrimidinyloxy)-3-methYlphenYl]-N'-[2-(diethylamino)benzoYl]urea (Compound No. 33 as described hereinafter) A solution of a mixture comprising 3.27 g of 4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl isocyanate, 2.05 g of 2-(diethylamino)benzamide and 30 me of toluene, was reacted at 100C for 3 hours.
After completion of the reaction, the solution mixture was cooled, and insoluble substances were removed by filtration. The filtrate thereby obtained was concentrated and purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 7:3) to obtain 1.45 g of the desired product --` 20218~6 (melting point: 39 ~ 43C, amorphous) (Compound No. 33 as described hereinafter).
Preparation of N-[2-(acetylamino)benzoyl~-N'-[4-(5-bromo-2-pyrimidinyloxyl-3-methylPhenyl]urea (ComPound No. 49 as described hereinafterl 1.3 g of N-(2-aminobenzoyl)-N'-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]urea (Compound No. 27 as described hereinafter) as prepared in accordance with Preparation Example 3, was added to 30 me of pyridine, and 0.25 ml of acetyl chloride was dropwise added thereto under cooling with ice. The mixture was stirred at room temperature for 2 hours and 30 minutes. Then, pyridine was distilled off, and the residue was purified by silica gel column chromatography (developing solvent; methylene chloride:ethyl acetate = 7:3) to obtain 1.18 g of the desired product (melting point: 186 - 191C) (Compound No. 49 as described hereinafter).
Now, typical examples of the compound of the formula (I) will be given in Table 1.
202~8~6 IV~ IU~ Tn E
. _ 1~ l U l l l l 1, In ~ ~ ~ ~ ~ ~
~O~ ~ ~ ~ ~ ~ ~ ~q Z~Z .rp~ tq~ ~~~ e~ c~ 0 ~ __ __ _ ___ U \ / N ~ ~ U r U u u u ~
~ ~Z; N U W U t~ ~.) ~J _ r ~ _ 1:~ P~ ~ 1~~ ~~4 U Cl ~
~1 ~ __ __ _ iL~_ -``- 202~8~L6 - l9 -C~ ~) ~ _ ~ _ _ a,~ ~ o,_ 1,0 ~ ,1 ~ ~ __ ~'i L LL L l _ _ _ _ o l l l I l L__ __ ___ _ U7 ~ ~J ~ ~ ~ ~ ~ ~ ~ ~ ~
~ ~ ~) ~ u ~ ~a ~ :~ a~ ~
~: ZN~ ~ ~ 1 ~ W~ ~
. __ _ _ _ N ~ ~ ~ ~_3 P:l tq U W ~:q P:~ tL~ ~ ¦I~
~\~;/ _ _ _ _ __ ___ N O P:~ tl~ P~ ~) t~ e~ 1~ O O ~
~a _ _ _ _ __ ____ ~; ~ P~ ~ p: ~ ~ ~ ~ m ~
o ~ _ _ _ _ _ _ _ L~L ~ L
--- 20218~6 ___ _ --~o~ _ _ o~ o o~
,o _ _ _ . _ __ _ _ _ , _ __ r 1~ 1~4 U H ~4 U U oN m m m _ _ _ ~; Pl:~ ~ ~ W~ W~ ~1~ W~ U ~q~ ~ L
_ _ _ _ _ ~q~ wr' ~ ~ ~ w ~\z/~ __ ~ ~ ___ _ PS ~r~ Pu~ p c~ tq ~q ~ m ~ l _~ _ _ N _ _ ~: ~; ~ P~ Z lm ~ ~ t~ p: ~ ~
o _ _ _ _ r I ~ r i O r-l ~N ~r 1~1 ~ ~1 Cl~ ~
~ UO Z _ ,,, 2021g~6 ~ _ --u U U U U _ g , o ~ o , o , o ~ O
~ ~ 1~ a~ ~ ~E~
~ P~ ~ ~ ~ p~ ,a P~ ~ ~ ~
~ l l l l l l l l l ~.~ __ __ ___ __ m _ m _ ~ ____ ~ W t~ N P:l W O O W W
~ ~ r~l ~ 1~1 ~ ~1 _ ~
__ _ ~~ ~ w~ w~ w~ m'n o w~ ~r~ c~
~\z/; - - [~z~ <~
N W W W W W W W
~:~ . _ _ O ~ W W W W W W W W W
O ~ _ r _ _ r~l ~1 N ~ ~r 1~ ~ t'l ~1 .a oz _ __ _l 202~846 ~ ~; ~ P;
~__ __ __ _ o l l l l I l l l l l _ l ___ ~ m m m a: m ~ H m m m -_ _ . _ _ ~ ur' m~ o ~, N p:~ ~q tqr ~q~r) ~r) U l l l r~ ~ rO ~ ~
___ _ _ ~ ~ ~; ~ m P~ w P~ ~ P~ ~, a $,~
P;\z/~; _ _ _ ___ ,, N t~l U U U U U tr ~ O U
~ _ _--r --r _ ~ ~; t~ P~ ~ t~ P: ~I~ ~ ~ ~ p:~
a ~ ____ _ ___r ~ o~ o ,~ ~ ~ ~r In ~ I~ 0 ~ ~ ~ . ~, ~
~0~18~6 _ _ _ a~ U c~ t~ ~) U c~ U
a~ a~ ~ ~ In ~ ~
O r--I ~1 r-l r--I r-l N ~`1 ~ ~ o ~ ~ a~ ~
~:
__ _ _ D (~ l l l l l l l . _ .
In ~1 ~1 S_l t-J 1-~ 1-1 ~_1 ~ _ _ m _ _ __ ~ W~ W~ pl:t~ W~ W~' W~ W~
l r~ ~ r~ ~ r~ r~ ~
P~ W D~r U O O O WX
\ /~; _ _ W W O -- ~ V
ra - ----- C~ l a ~:m ~ ~ P: e~ w w t~ ~a_ . _ -- n ~ ~ tJ~ O ~1 t~ t`~ ~r u~ ~
E~ ; U Z _ 02~8~6 Compound No. 56:
N-[3-(5-chloro-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea (melting point: 134 -136.5C) Compound No. 57:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea Compound No. 58:
N-[3-(5-chloro-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea Compound No. 59:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea Compound No. 60:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-trifluoromethylphenyl]-N'-[2-(dimethylamino)benzoyl]urea Compound No~ 61:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-trifluoromethylphenyl]-N'-[2-(diethylamino)benzoyl]urea The compound of the formula (I) is effective against experimental murine tumors such as P-388 leukemia, L-1210 leukemia, B-16 melanoma, M-5076 sarcoma, Colon 3~, Colon 26 and Lewis lung carcinoma. On the other hand, certain in vivo test systems and protocols have been developed by National Cancer Institute for testing compounds to -` ~02~46 determine their suitabilities as antineoplastic agents.
These have been reported in "Cancer Chemotherapy Reports", Part III, Vol. 3, No. 2 (1972) written by Deran, Greenberg, MacDonald, Schumacher and Abott. These protocols have established standarized screening tests which are generally followed in the field o~ testing for antitumour agents. Among these systems, P-388 leukemia is particularly significant for the present invention.
These neoplasms were discovered in mice. Excellent antitumour activities indicated by the percent increase of the medium servival time of treated animals (T) over control animals (C) in these protocols, generally suggest the same results against human leukemia.
Now, the antitumour activity, solubility in a non-aqueous solvent, doses and methods of administration ofthe compounds of the formula (I) will be described.
These compounds exhibit excellent antitumour activities.
(1-1) Antitumour activity TEST EXAMPLE 1 (Intraperitoneally transplanted -intraperitoneally administered) 1 x 106 of P-388 leukemia cells per mouse were intraperitoneally transplanted into BDF1 mouse. Each formulation was intraperitoneally administered on days 1 and 8 after the transplantation.
The mortality was observed for 30 days. The increase life span of each group was determined on such basis that the medium survival time of a control group to which ` -`` 202~8~6 physiological saline was administered was regarded to be 0% of increase life span (ILS). The results are shown in Table 2. Among the tested formulations, compound 2 was formulated in accordance with the below-mentioned Formulation Example 9, and the rest was formulated in accordance with the below-mentioned Formulation Example 8.
.
~ ' ' ' .
. .
` 202~8~
Table 2 _ __ Increase Compound Dose life span*
No. (Active ingredient mg/kg/day) (ILS) (%) 12.5 126 _ 12.5 _94 12.5 50 _ 9 12.5 80 _ 12.5 39 _ .
11 ~1 132 . _ .
>137 26 12.5 93 . _ .~
34 6.25 49 _ -` ~02~8~6 Table 2 (continued) _ . . _ Increase Compound Dose No. (Active ingredient mg/kg/day) (ILS) (%) 27 12.55 126 . _ __ . __ _ _ _ _ _ 52 6.2255 139 (Note) * Increase life span is calculated by the following equation:
Increase life span % (ILS3 =
Median survival time of test qroup x lOO) - loo Median survival time of control animals (1-2) Antitumour activity TEST EXAMPLE 2 (intraperitoneally transplanted -intravenously injected) l x 106 of P-388 leukemia cells per mouse were intraperitoneally transplanted to BDFl mouse. Each formulation (formulated in accordance with the below-mentioned Formulation Example lO) was intravenously injected from the tail on days l and 8 after the transplantation.
The mortality was observed for 30 days. The increase life span (ILS, %) of each treated group was determined on such basis that the median survival time of a control group to which a physiolosical saline was administered was regarded to be 0% of increase life span (ILS). In the cases where Compounds No. l and No. ll were administered at a dose (active ingredient mg/kg/day) of 10 mg/kg, ILS (%) was 46 and 27, respectively.
(Note) * The increase life span was calculated in the same manner as in Test Example 1.
(2) Solubility to a non-aqueous solvent A stirring magnet was put into a lO me or lO0 me egg plant flask e~uipped with a stopper, and 50 mg of a test compound was introduced into this flask. Furtherl a suitable amount of a desired solvent was introduced thereinto, and the solubility was determined. The results are shown in Table 3 (the temperature at the time 2~2~
of measuring the solubility was from 18 to 20C).
Table 3 Solubili ty (~) Compound No.
Medlum chain Soybean oil triglyceride _ 1 2.1 - 2.3 0.46 - 0.49 11 1.5 - 1.8 0.15 -- 0.16 . __ 33 at least 13.6 i (Note) As the medium chain triglyceride, ODO, tradename, manufactured by Nisshin Seiyu K.K., was employed.
2 0 ~
- 31 ~
(3) Dose and method for administration As the method for administration, in the case of animals, drugs may be administered by injection such as intraperitoneal injection, intravenous injection or local administration, or by oral administration. In the case of human being, drugs may be administered by injection such as intravascular injection to a vein or an arteria or local administration, by oral administration, or as a suppository. The dose is determined in view of the results of animal experiments and various conditions within a range that the total amount does not exceed a certain amount. Drugs may be administered continuously or intermittently. However, the dose may optionally vary depending upon the method for administration, the patient or the condition of an animal to be treated such as age, body weight, sex, sensitivity, food, time of administration, drugs used together or degree of the patient or the disease. The suitable amount and the numbers of administration under a certain condition, must be determined by the determination test of a suitable amount by a specialist based on the above guidelines.
The antitumour agent of the present invention may be formulated in the same manner as in the case of usual drugs. It is formulated from the active ingredient and various pharmaceutically acceptable adjuvants such as an inert diluent. The formulation can be administered ` 202~8~6 orally or intravenously, or in the form of a suppository.
Further, the content of the active ingredient in the antitumour agent of the present invention varies depending upon the difference of various conditions and can not generally be defined. The agent may contain the active ingredient in the same manner as in the case of usual antitumour agents. For example, it may contain at least 0.1% of the active ingredient.
The compound of the formula (I) may be formulated, for example, into a suppository or a capsule by directly mixing the compound with polyethylene glycol, or into an aqueous suspension. When the compound of the formula (I) is formulated into an aqueous suspension, as the method for formulating an aqueous suspension which does not contain a phospholipid, there may be mentioned, for example, a method wherein the active ingredient compound previously formed into fine powder, is added to an aqueous solution containing a surfactant and, if necessary, a defoaming agent, the mixture is then subjected to wet pulverization to obtain particles having a particle size of at most 5 ~m, for example, particles of which 80% have a particle size of at most 2 ~um, and, if necessary, a thickener is added thereto. The surfactant includes, for example, polyoxyethylene hardened castor oil, polyoxyethylene sorbitol fatty acid ester, sucrose ester, polyoxyethylene-polyoxypropylene 2~18~6 block polymer and oxyethylated polyarylphenol phosphate.
The defoaming agent includes, for example, dimethylpolysiloxane, methylphenylsiloxane, sorbitol fatty acid ester, polyoxyethylene polyoxypropylenecetyl ether and silicone. The thickener includes, for example, Gua gum, arginic acid, gum arabic, pectin, starch, xanthane gum and gelatin. On the other hand, as the method for formulating an aqueous suspension containing a phospholipid, there may be mentioned, for example, a method wherein a phospholipid such as soybean phospholipid or yolk phospholipid is used instead of the surfactant used in the above method, and an antioxidant such as a-tocopherol is used instead of the thickener.
Further, these formulations may be formed into tablets, capsules, enteric coated tablets, powders, injection solutions or suppositorties by usual methods commonly employed in the field of formulation.
The compounds of the present invention are readily soluble in pharmaceutically acceptable non-aqueous solvents such as medium chain triglyceride, soybean oil, sesami oil, olive oil, tsubaki oil, rapeseed oil1 corn oil, peanut oil and cotton seed oil. Accordingly, they can readily be formulated into fatty emulsions for intravenous injection. As a method for formulating such fatty emulsions, there may be mentioned, for example, a method in which a compound of the present invention and a phospholipid are dissolved, if necessary, together with an emulsifying adjuvant and an emulsion stabilizer, in the above-mentioned non-aqueous solvent, and water is added, followed by homogenizing the dispersion by a homogenizer to bring the average particle size to a level of not more than 1.0 ~m. As the phospholipid used here, purified yolk phospholipid or soybean phospholipid may be mentioned. As the emulsifying adjuvant, a pharmaceutically acceptable fatty acid having from 6 to 22 carbon atoms, or its alkali metal salt such as a sodium or potassium salt or its alkaline earth metal salt such as a calcium salt, may be employed. As the emulsion stabilizer, cholesterol or phosphatidic acid, may be mentioned. Further, an isotonic agent such as glycerol or glucose may be added to make this fatty emulsion isotonic. The homogenizer used here, may be a pressure spray type homogenizer or an ultrasonic homogenizer.
Now, specific Formulation Examples of the antitumour agent of the present invention will be mentioned.
70 mg of non-crystalline powder of the afore-mentioned Compound No. l was thoroughly mixed with 30 mg of lactose, and mixture was filled in capsules in an amount of 100 mg per capsule to obtain capsules for oral administration.
86.5 parts by weight of the non-crystalline powder of the afore-mentioned Compound No. 3 was uniformly mixed 20218~6 with l part by weight of glucose, 10 parts by weight of corn starch and 1.5 parts by weight of a 5% corn starch paste solution. The mixture was formed to granules by a wet method. Then, l part by weight of magnesium stearate was added thereto, and the mixture was tabletted by compression to obtain tablets for oral administration.
Our Ref.: IH-78 SUBSTITUTED BENZOYLUREA COMPOUNDS OR THEIR SALTS, PROCESSES FOR THEIR PRODUCTION AND ANTITUMOUR
COMPOSITIONS CONTAINING THEM
The present invention relates to novel substituted benzoylurea compounds or their salts, having an N-substituted benzoyl group on one side of the urea chain and a substituted pyrimidinyloxyphenyl group on the other side, processes for their production, intermediates thereof, compositions for treating a cancer such as leukemia, melanoma, sarcoma or carcinoma which comprise the substituted benzoylurea compounds or their salts, and a method for treating such a cancer.
Those similar to the substituted benzoylurea compounds of the present invention are disclosed in European Patent Publication No. 193249. However, the compounds of the present invention are different from them in the chemical structure with respect to the substituent bonded to the phenyl ring directly bonded to the urea group. Further, the compounds of the present invention are superior in the antitumour activities to 20218~6 the compounds disclosed in the above publication.
Further, European Patent Publication No. 335~08 discloses benzoylurea compounds. However, these compounds and the compounds of the present invention are different in the chemical structure with respect to the presence or absence of the substituent at the carbon atom or the nitrogen atom of the carbonylurea chain and with respect to the type of the substituent to the amino group as the substituent on the benzoyl group.
Further, the compounds of the present invention are superior to the conventional benzoylurea compounds in the solubility to a non-aqueous solvent.
The present inventors have found that the substituted benzoylurea compounds of the following formula (I) and their salts show a high level of antitumour activities, and they have an improved solubility in a non-aqueous solvent while the conventional benzoylurea compounds tend to be hardly soluble in a non-aqueous solvent. The present invention has been accomplished on the basis of these discoveries.
The present invention provides a substituted benzoylurea compound of the formula (I):
~ - CONHCONH
~21846 -wherein Rl is a hydrogen atom, a halogen atom or a nitro group, each of R2 and R3 is a hydrogen atom, an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 twherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt.
The present invention also provides processes for the production of the compound of the formula (I) or its salt, an intermediate thereof, a composition for treating a cancer such as leukemia, melanoma, sarcoma or carcinoma, which comprises the compound of the formula lI) or its salt, and a method for treating such a cancer.
Now, the present invention will be described in detail with reference to the preferred embodiments.
In the formula (I), the substituent of the substituted alkyl group, the substituted alkoxy group and the substituted alkylthio group in the definition of R4 includes, for example, a halogen atom, an alkoxy group, an alkylthio group, a cyano group, a thiocyanate group, an alkoxycarbonyl group, a carboxyl group and an alkylthiocarbonyl group. The substituent of the substituted alkyl group in the definition of R5 may be a 202~8~6 halogen atom. The number of substituents contained in R4 and R5 may be one or more.
The heterocyclic group formed by R2 an~ R3 together with the adjacent nitrogen atom, may be a morpholino group, an aziridinyl group, a pyrrolidinyl group, a piperidino group or a pyrrolyl group.
The salt of the benzoylurea compound of the present invention may be any salt so long as it is pharmaceutically acceptable. For example, it may be a salt of a hydrogen halide such as hydrochloric acid or hydrobromic acid, or a salt of an alkali metal such as sodium or potassium, or of an alkaline earth metal such as magnesium or calcium.
The halogen atom in the definition of Rl, R4 and R5, includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
In the formula (I), the alkyl moiety constituting the alkyl group and the alkoxy group in the definition of R2 and R3, the alkyl moiety constituting the substituted or unsubstituted alkyl group, the substituted or unsubstituted alkoxy group and the substituted or unsubstituted alkylthio group in the definition of R4, the alkyl moiety constituting the substituted or unsubstituted alkyl group in the deti.mition of R5, and 2S the alkyl moiety constituting the alkoxy group, the alkylthio group, the alkoxycarbonyl group or the alkylthio carbonyl group as the substituent of the 2021~6 substituted alkyl group, the substituted alkoxy group and the substituted alkylthio group in the definition of R4, is preferably an alkyl group having from 1 to 10 carbon atoms such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group or a decyl group, more preferably an alkyl group having from 1 to 4 carbon atoms. Further, these alkyl group also include linear or branched aliphatic chain structural isomers.
In the above formula (I), a substituted benzoylurea compound of the following formula (I') or its salt, is preferred:
~ 2 ~ -< ~ R5 (I ) N ~R R4 wherein Rl, R2, R3, R4 and R5 are as defined above.
Rl is preferably a hydrogen atom. Each of R2 and R3 is preferably an alkyl group. Also preferably, R2 and R3 form together with the adjacent nitrogen atom a heterocyclic ring. R4 iS preferably a halogen atom or a substituted or unsubstituted alkyl group, more preferably a substituted or unsubstituted alkyl group. R5 is preferably a halogen atom. The following compounds are preferred among the substituted benzoylurea compounds of the formula (I) and their salts:
. .
, N-[4-(5-bromo-2-pyrimidinyloxy)-3 methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea hydrochloride, N-[4-(5-bromo-2-pyrimidinyloxy)-3-trifluoromethylphenyl]-N'-[2-(dimethylamin~)benzoyl]urea, N-[4-(5-chloro-2-pyrimidinyloxy)-3-trifluoromethylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea, and N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea.
lS The benzoyl urea compound of the formula (I) can be prepared by the following methods:
(A) R
Hal ~ O ~ O } ~5 + HN < ~~~ (I
(II) (III) wherein Rl, R2, R3, R.4 and R5 are as defined above, and Hal is a halogen atom.
This reaction is conducted usually at a temperature of from 0C to a reflux temperature, and the reaction time is usually from 1 to 24 hours. A solvent may be used for this reaction. Such a solvent includes, for example, benzene, toluene, xylene, chlorobenzene, hexane, chloroform, methylene chloride, dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylsulfoxide, hexamethylphosphoric triamide, and water.
(B) R
10~ R2I ~ O ~ O } R
(IV) (V) Rl 5 ~~~ ~ - CONHCONH ~ ~ O } R5 (I-l) \ R3 R4 wh~rein Rl, R~ and R5 are as defined above, each of Al and A2 is -NCO or -NH2, provided that when Al is -NCO, A2 is -NH2, and when Al is -NH2, A2 is -NCO, and each of R2 and R3 is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring.
This reaction is conducted usually in the presence of a solvent at a temperature of from 0C to a reflux 2021~
temperature, and the reaction time is usually from 1 to 24 hours. The solvent includes, for example, benzene, toluene, xylene, chlorobenzene, hexane, chloroform, methylene chloride, dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylsulfoxide and hexamethylphosphoric triamide.
(C) ~ CONHCONH ~~N~ S hydr~zine N-Bl R4 ( VI ) (~ CONHCONH ~O --~ ~KS
( I - 2 ) wherein Rl, R4 and R5 are as defined above, and Bl is a phthaloyl group.
The hydrazine may be hydrazine, an alkyl hydrazine or phenyl hydrazine.
~ his reaction is conducted usually in the presence of a solvent at a temperature of from 0C to a reflux temperature, and the reaction time is usually from 1 to 24 hours. The solvent includes, for example, methanol, ethanol, chloroform, and methylene chloride.
-- 20218~6 (D) Rl l (C~ CONHCONH ~ ~\ ~--R5~ reduction IVII ) Rl l ~ CONHCONH ~O --~ (~--R5 \NH2 R4 ' ( I - 3 ) wherein Rl is a hydrogen atom or a halogen atom, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group or a substituted or unsubstituted alkylthio group, and R5 is a halogen atom or a substituted or unsubstituted alkyl group.
This reaction is conducted in accordance with a usual reduction method. The reduction method may, for example, be a redu~tion method using a metal such as reduced iron or zinc, or a catalytic reduction method using a catalyst such as platinum or palladium-carbon. The reaction is conducted usually at a temperature of from 0C to a reflux temperature, and the reaction time is usually from 1 to 100 hours.
( E ) Rl ~ CONHCONH <~ ~ O}R5 ~Ia1 R (VIII) (I-2) Rl <~ ~ R2 " ~-- N }
\H R4 (IX) wherein Rl, R4 and R5 are as defined above, and R2 is an alkyl group.
This reaction is conducted usually at a temperature of from 0C to a reflux temperature, and the reaction lS time is usually from 0.1 to 24 hours. A solvent and a base may be used for this reaction. The solvent includes, for example, benzene, toluene, xylene, chlorobenzene, pyridine, hexane, cyclohexane, chloroform, methylene chloride, dichloroethane, diethyl ether, tetrahydrofuran, dioxane, ethyl acetate, dimethylformamide, dimethylsulfoxide and hexamethylphosphoric triamide. The base includes an organic lithium such as n-butyl lithium, tert-butyl lithium or phenyl lithium, an inorganic base such as sodium hydroxide, potassium hydroxide, sodium hydride or ; potassium hydride, and an organic base such as triethylamine or pyridine.
- 20218~6 (F) ~/R2~ } 5 Ual - R3 (X) N\H R4 ( IX ) <~R3 ~ ~ ~O}R5 R3~
(XI) . wherein Rl, R2 , R4 and Rs are as defined above, and R3 is an alkyl group.
lS The reaction conditions may be the same as described above with respect to (E).
Eurther, the compounds of the formula (II) and (VII) can be prepared in accordance with the above method (B).
A compound of the formula (IV) wherein Al is -NH2, can be prepared, for example, by reacting a 2-halogenobenzamide with a secondary amine of the formula (III) in accordance with the above method (A), and a compound wherein Al is -NCO can be prepared by reacting the benzamide obtained by the above method, with oxalyl chloride at a temperature of from 0C to a reflux temperature for from 1 to 100 hours in the presence of the same solvent as mentioned in the above method (B). Further, a compound of the formula ~02~
(VI) can be prepared in accordance with the above method (B) by using either a benzamide obtained by reacting a ~-aminobenzamide with phthalic anhydride at a tempe~ature of from 0C to a reflux temperature for from l to lO0 hours in the presence of a solvent such as chloroform, methylene chloride or pyridine, or an isocyanate obtained by reacting the benzamide obtained by the above-mentioned method, with oxalyl chloride at a temperature of from 0C
to a refluxing temperature for 1 to lO0 hours in the presence of the same solvent as mentioned in the above method (B).
Further, the salt of the substituted benzoylurea compound can readily be obtained by a usual production method.
Among the compounds of the formula (IV), those wherein R2 and R3 are -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above) (as represented by the following formula (XII)) are novel. Among the compounds of the formula ~XII), those wherein Al is -NH2 are preferred.
Rl ~ -COAl (XII) N
wherein each of R2 and R3 is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or ` 2021846 -SO2R6 (wherein R6 is as defined above), provided that either one of R2 and R3 is -COR6 or -SO2R6, and and Al are as defined above.
Now, specific Preparation Examples of the compounds of the formula (I) will be described.
Preparation of N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoYl~urea (Compound No. 1 as described hereinafter) A solution of a mixture comprising 3.73 g of 4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl isocyanate, 2.0 g of 2-(dimethylamino)benzamide and 45 me of toluene, was reacted under reflux for 4 hours.
After completion of the reaction, the mixture was cooled, and insoluble substances were removed by filtration. The filtrate thereby obtained was concentrated and purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 6:4) to obtain 3.9 g of the desired product (melting point: 98 - 104C) (Compound No. 1 as described hereinafter).
PREPARAT~ON EXAMPLE 2 Preparation of N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenYl]-N'-[2-(dimethYlamino)benzoYl]urea hydrochloride (Compound No. 2 as described hereinafter) 1.5 g of the desired product obtained in Example 1 (Compound No. 1 as described hereinafter) was dissolved ~ .
' 20218~
in 20 me of diethyl ether and 50 me of methylene chloride, and hydrochloric acid gas was introduced to the solution and saturated therein.
Thereafter, the saturated solution was stirred for one hour and then cooled, and precipitated crystals were collected by filtration. The crystals thus obtained were washed with diethyl ether to obtain 1.55 g of the desired product (melting point: 117 - 123C) (Compound No. 2 as described hereinafter).
Preparation of N-(2-aminobenzoyl)-N'-[4-(5-bromo-2-PYrimidinYloxY)-3-chlorophenyl]urea (Compound No. 26 as described hereinafter) A mixture comprising 1.0 g of N-[4-(5-bromo-2-; 15 pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoyl)urea and 30 me of glacial acetic acid, was heated to 80C, and 0.57 g of reduced iron was gradually added thereto under stirring. Thereafter, the mixture was stirred and reacted at the same temperature for 30 minutes.
After completion of the reaction, the reaction mixture was poured into water, and the insoluble product was collected by filtration. ~he collected insoluble product was dxied under vacuum and purified by silica gel column chromatography ~developing solvent; n-hexane:ethyl acetate = 7:3) to obtain 0.4 g of the desired product (melting point: 196 - 200C) (Compound No. 26 as described hereinafter).
--- 202~8~6 Preparation of N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-(2-morpholinobenzoyl)urea (Compound No.
34 as described hereinafter) (1) 5 g of 2-fluorobenzamide and 25 me of morpholine were reacted in an autoclave at 100C for 18 hours.
After completion of the reaction, the reaction product was cooled, and excess morpholine was distilled off. The residue was purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 3:7) to obtain 2.8 g of 2-morpholinobenzamidé
(melting point: 112 - 119C).
(2) A solution obtained by dissolving 3.28 g of 4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl isocyanate in 30 me of toluene, was dropwise added to 2.21 g of 2-morpholinobenzamide obtained in the above step (1) under stirring. Thereafter, the mixture was reacted at 100C
for 3 hours.
After completion of the reaction, toluene was distilled off, and the residue was purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 1:1) to obtain 1.25 g of the desired product (melting point: 67 - 70C, amorphous) (Compound No. 34 as described hereinafter).
Preparation of N-[4-(5-chloro-2-pyrimidinyloxy)-3-methYlphenyl]-N'-[2-(dimethylamino)benzoyl]urea (Compound 202184~
No. 11 as described hereinafter) A solution of a mixture comprising 3.33 g of 4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl isocyanate, 2.1 g of 2-(dimethylamino)benzamide and 30 me of toluene, was reacted at 100C for 4 hours.
After completion of the reaction, the solution mixture was cooled, and insoluble substances were removed by filtration. The filtrate thereby obtained was concentrated and purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 6:4) to obtain 2.84 g of the desired product (melting point: 48 - 52C, amorphous) (Compound No. 11 as described hereinafter).
Preparation of N-[4-(5-bromo-2-pYrimidinyloxy)-3-methYlphenYl]-N'-[2-(diethylamino)benzoYl]urea (Compound No. 33 as described hereinafter) A solution of a mixture comprising 3.27 g of 4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl isocyanate, 2.05 g of 2-(diethylamino)benzamide and 30 me of toluene, was reacted at 100C for 3 hours.
After completion of the reaction, the solution mixture was cooled, and insoluble substances were removed by filtration. The filtrate thereby obtained was concentrated and purified by silica gel column chromatography (developing solvent; n-hexane:ethyl acetate = 7:3) to obtain 1.45 g of the desired product --` 20218~6 (melting point: 39 ~ 43C, amorphous) (Compound No. 33 as described hereinafter).
Preparation of N-[2-(acetylamino)benzoyl~-N'-[4-(5-bromo-2-pyrimidinyloxyl-3-methylPhenyl]urea (ComPound No. 49 as described hereinafterl 1.3 g of N-(2-aminobenzoyl)-N'-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]urea (Compound No. 27 as described hereinafter) as prepared in accordance with Preparation Example 3, was added to 30 me of pyridine, and 0.25 ml of acetyl chloride was dropwise added thereto under cooling with ice. The mixture was stirred at room temperature for 2 hours and 30 minutes. Then, pyridine was distilled off, and the residue was purified by silica gel column chromatography (developing solvent; methylene chloride:ethyl acetate = 7:3) to obtain 1.18 g of the desired product (melting point: 186 - 191C) (Compound No. 49 as described hereinafter).
Now, typical examples of the compound of the formula (I) will be given in Table 1.
202~8~6 IV~ IU~ Tn E
. _ 1~ l U l l l l 1, In ~ ~ ~ ~ ~ ~
~O~ ~ ~ ~ ~ ~ ~ ~q Z~Z .rp~ tq~ ~~~ e~ c~ 0 ~ __ __ _ ___ U \ / N ~ ~ U r U u u u ~
~ ~Z; N U W U t~ ~.) ~J _ r ~ _ 1:~ P~ ~ 1~~ ~~4 U Cl ~
~1 ~ __ __ _ iL~_ -``- 202~8~L6 - l9 -C~ ~) ~ _ ~ _ _ a,~ ~ o,_ 1,0 ~ ,1 ~ ~ __ ~'i L LL L l _ _ _ _ o l l l I l L__ __ ___ _ U7 ~ ~J ~ ~ ~ ~ ~ ~ ~ ~ ~
~ ~ ~) ~ u ~ ~a ~ :~ a~ ~
~: ZN~ ~ ~ 1 ~ W~ ~
. __ _ _ _ N ~ ~ ~ ~_3 P:l tq U W ~:q P:~ tL~ ~ ¦I~
~\~;/ _ _ _ _ __ ___ N O P:~ tl~ P~ ~) t~ e~ 1~ O O ~
~a _ _ _ _ __ ____ ~; ~ P~ ~ p: ~ ~ ~ ~ m ~
o ~ _ _ _ _ _ _ _ L~L ~ L
--- 20218~6 ___ _ --~o~ _ _ o~ o o~
,o _ _ _ . _ __ _ _ _ , _ __ r 1~ 1~4 U H ~4 U U oN m m m _ _ _ ~; Pl:~ ~ ~ W~ W~ ~1~ W~ U ~q~ ~ L
_ _ _ _ _ ~q~ wr' ~ ~ ~ w ~\z/~ __ ~ ~ ___ _ PS ~r~ Pu~ p c~ tq ~q ~ m ~ l _~ _ _ N _ _ ~: ~; ~ P~ Z lm ~ ~ t~ p: ~ ~
o _ _ _ _ r I ~ r i O r-l ~N ~r 1~1 ~ ~1 Cl~ ~
~ UO Z _ ,,, 2021g~6 ~ _ --u U U U U _ g , o ~ o , o , o ~ O
~ ~ 1~ a~ ~ ~E~
~ P~ ~ ~ ~ p~ ,a P~ ~ ~ ~
~ l l l l l l l l l ~.~ __ __ ___ __ m _ m _ ~ ____ ~ W t~ N P:l W O O W W
~ ~ r~l ~ 1~1 ~ ~1 _ ~
__ _ ~~ ~ w~ w~ w~ m'n o w~ ~r~ c~
~\z/; - - [~z~ <~
N W W W W W W W
~:~ . _ _ O ~ W W W W W W W W W
O ~ _ r _ _ r~l ~1 N ~ ~r 1~ ~ t'l ~1 .a oz _ __ _l 202~846 ~ ~; ~ P;
~__ __ __ _ o l l l l I l l l l l _ l ___ ~ m m m a: m ~ H m m m -_ _ . _ _ ~ ur' m~ o ~, N p:~ ~q tqr ~q~r) ~r) U l l l r~ ~ rO ~ ~
___ _ _ ~ ~ ~; ~ m P~ w P~ ~ P~ ~, a $,~
P;\z/~; _ _ _ ___ ,, N t~l U U U U U tr ~ O U
~ _ _--r --r _ ~ ~; t~ P~ ~ t~ P: ~I~ ~ ~ ~ p:~
a ~ ____ _ ___r ~ o~ o ,~ ~ ~ ~r In ~ I~ 0 ~ ~ ~ . ~, ~
~0~18~6 _ _ _ a~ U c~ t~ ~) U c~ U
a~ a~ ~ ~ In ~ ~
O r--I ~1 r-l r--I r-l N ~`1 ~ ~ o ~ ~ a~ ~
~:
__ _ _ D (~ l l l l l l l . _ .
In ~1 ~1 S_l t-J 1-~ 1-1 ~_1 ~ _ _ m _ _ __ ~ W~ W~ pl:t~ W~ W~' W~ W~
l r~ ~ r~ ~ r~ r~ ~
P~ W D~r U O O O WX
\ /~; _ _ W W O -- ~ V
ra - ----- C~ l a ~:m ~ ~ P: e~ w w t~ ~a_ . _ -- n ~ ~ tJ~ O ~1 t~ t`~ ~r u~ ~
E~ ; U Z _ 02~8~6 Compound No. 56:
N-[3-(5-chloro-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea (melting point: 134 -136.5C) Compound No. 57:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea Compound No. 58:
N-[3-(5-chloro-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea Compound No. 59:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea Compound No. 60:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-trifluoromethylphenyl]-N'-[2-(dimethylamino)benzoyl]urea Compound No~ 61:
N-[3-(5-bromo-2-pyrimidinyloxy)-4-trifluoromethylphenyl]-N'-[2-(diethylamino)benzoyl]urea The compound of the formula (I) is effective against experimental murine tumors such as P-388 leukemia, L-1210 leukemia, B-16 melanoma, M-5076 sarcoma, Colon 3~, Colon 26 and Lewis lung carcinoma. On the other hand, certain in vivo test systems and protocols have been developed by National Cancer Institute for testing compounds to -` ~02~46 determine their suitabilities as antineoplastic agents.
These have been reported in "Cancer Chemotherapy Reports", Part III, Vol. 3, No. 2 (1972) written by Deran, Greenberg, MacDonald, Schumacher and Abott. These protocols have established standarized screening tests which are generally followed in the field o~ testing for antitumour agents. Among these systems, P-388 leukemia is particularly significant for the present invention.
These neoplasms were discovered in mice. Excellent antitumour activities indicated by the percent increase of the medium servival time of treated animals (T) over control animals (C) in these protocols, generally suggest the same results against human leukemia.
Now, the antitumour activity, solubility in a non-aqueous solvent, doses and methods of administration ofthe compounds of the formula (I) will be described.
These compounds exhibit excellent antitumour activities.
(1-1) Antitumour activity TEST EXAMPLE 1 (Intraperitoneally transplanted -intraperitoneally administered) 1 x 106 of P-388 leukemia cells per mouse were intraperitoneally transplanted into BDF1 mouse. Each formulation was intraperitoneally administered on days 1 and 8 after the transplantation.
The mortality was observed for 30 days. The increase life span of each group was determined on such basis that the medium survival time of a control group to which ` -`` 202~8~6 physiological saline was administered was regarded to be 0% of increase life span (ILS). The results are shown in Table 2. Among the tested formulations, compound 2 was formulated in accordance with the below-mentioned Formulation Example 9, and the rest was formulated in accordance with the below-mentioned Formulation Example 8.
.
~ ' ' ' .
. .
` 202~8~
Table 2 _ __ Increase Compound Dose life span*
No. (Active ingredient mg/kg/day) (ILS) (%) 12.5 126 _ 12.5 _94 12.5 50 _ 9 12.5 80 _ 12.5 39 _ .
11 ~1 132 . _ .
>137 26 12.5 93 . _ .~
34 6.25 49 _ -` ~02~8~6 Table 2 (continued) _ . . _ Increase Compound Dose No. (Active ingredient mg/kg/day) (ILS) (%) 27 12.55 126 . _ __ . __ _ _ _ _ _ 52 6.2255 139 (Note) * Increase life span is calculated by the following equation:
Increase life span % (ILS3 =
Median survival time of test qroup x lOO) - loo Median survival time of control animals (1-2) Antitumour activity TEST EXAMPLE 2 (intraperitoneally transplanted -intravenously injected) l x 106 of P-388 leukemia cells per mouse were intraperitoneally transplanted to BDFl mouse. Each formulation (formulated in accordance with the below-mentioned Formulation Example lO) was intravenously injected from the tail on days l and 8 after the transplantation.
The mortality was observed for 30 days. The increase life span (ILS, %) of each treated group was determined on such basis that the median survival time of a control group to which a physiolosical saline was administered was regarded to be 0% of increase life span (ILS). In the cases where Compounds No. l and No. ll were administered at a dose (active ingredient mg/kg/day) of 10 mg/kg, ILS (%) was 46 and 27, respectively.
(Note) * The increase life span was calculated in the same manner as in Test Example 1.
(2) Solubility to a non-aqueous solvent A stirring magnet was put into a lO me or lO0 me egg plant flask e~uipped with a stopper, and 50 mg of a test compound was introduced into this flask. Furtherl a suitable amount of a desired solvent was introduced thereinto, and the solubility was determined. The results are shown in Table 3 (the temperature at the time 2~2~
of measuring the solubility was from 18 to 20C).
Table 3 Solubili ty (~) Compound No.
Medlum chain Soybean oil triglyceride _ 1 2.1 - 2.3 0.46 - 0.49 11 1.5 - 1.8 0.15 -- 0.16 . __ 33 at least 13.6 i (Note) As the medium chain triglyceride, ODO, tradename, manufactured by Nisshin Seiyu K.K., was employed.
2 0 ~
- 31 ~
(3) Dose and method for administration As the method for administration, in the case of animals, drugs may be administered by injection such as intraperitoneal injection, intravenous injection or local administration, or by oral administration. In the case of human being, drugs may be administered by injection such as intravascular injection to a vein or an arteria or local administration, by oral administration, or as a suppository. The dose is determined in view of the results of animal experiments and various conditions within a range that the total amount does not exceed a certain amount. Drugs may be administered continuously or intermittently. However, the dose may optionally vary depending upon the method for administration, the patient or the condition of an animal to be treated such as age, body weight, sex, sensitivity, food, time of administration, drugs used together or degree of the patient or the disease. The suitable amount and the numbers of administration under a certain condition, must be determined by the determination test of a suitable amount by a specialist based on the above guidelines.
The antitumour agent of the present invention may be formulated in the same manner as in the case of usual drugs. It is formulated from the active ingredient and various pharmaceutically acceptable adjuvants such as an inert diluent. The formulation can be administered ` 202~8~6 orally or intravenously, or in the form of a suppository.
Further, the content of the active ingredient in the antitumour agent of the present invention varies depending upon the difference of various conditions and can not generally be defined. The agent may contain the active ingredient in the same manner as in the case of usual antitumour agents. For example, it may contain at least 0.1% of the active ingredient.
The compound of the formula (I) may be formulated, for example, into a suppository or a capsule by directly mixing the compound with polyethylene glycol, or into an aqueous suspension. When the compound of the formula (I) is formulated into an aqueous suspension, as the method for formulating an aqueous suspension which does not contain a phospholipid, there may be mentioned, for example, a method wherein the active ingredient compound previously formed into fine powder, is added to an aqueous solution containing a surfactant and, if necessary, a defoaming agent, the mixture is then subjected to wet pulverization to obtain particles having a particle size of at most 5 ~m, for example, particles of which 80% have a particle size of at most 2 ~um, and, if necessary, a thickener is added thereto. The surfactant includes, for example, polyoxyethylene hardened castor oil, polyoxyethylene sorbitol fatty acid ester, sucrose ester, polyoxyethylene-polyoxypropylene 2~18~6 block polymer and oxyethylated polyarylphenol phosphate.
The defoaming agent includes, for example, dimethylpolysiloxane, methylphenylsiloxane, sorbitol fatty acid ester, polyoxyethylene polyoxypropylenecetyl ether and silicone. The thickener includes, for example, Gua gum, arginic acid, gum arabic, pectin, starch, xanthane gum and gelatin. On the other hand, as the method for formulating an aqueous suspension containing a phospholipid, there may be mentioned, for example, a method wherein a phospholipid such as soybean phospholipid or yolk phospholipid is used instead of the surfactant used in the above method, and an antioxidant such as a-tocopherol is used instead of the thickener.
Further, these formulations may be formed into tablets, capsules, enteric coated tablets, powders, injection solutions or suppositorties by usual methods commonly employed in the field of formulation.
The compounds of the present invention are readily soluble in pharmaceutically acceptable non-aqueous solvents such as medium chain triglyceride, soybean oil, sesami oil, olive oil, tsubaki oil, rapeseed oil1 corn oil, peanut oil and cotton seed oil. Accordingly, they can readily be formulated into fatty emulsions for intravenous injection. As a method for formulating such fatty emulsions, there may be mentioned, for example, a method in which a compound of the present invention and a phospholipid are dissolved, if necessary, together with an emulsifying adjuvant and an emulsion stabilizer, in the above-mentioned non-aqueous solvent, and water is added, followed by homogenizing the dispersion by a homogenizer to bring the average particle size to a level of not more than 1.0 ~m. As the phospholipid used here, purified yolk phospholipid or soybean phospholipid may be mentioned. As the emulsifying adjuvant, a pharmaceutically acceptable fatty acid having from 6 to 22 carbon atoms, or its alkali metal salt such as a sodium or potassium salt or its alkaline earth metal salt such as a calcium salt, may be employed. As the emulsion stabilizer, cholesterol or phosphatidic acid, may be mentioned. Further, an isotonic agent such as glycerol or glucose may be added to make this fatty emulsion isotonic. The homogenizer used here, may be a pressure spray type homogenizer or an ultrasonic homogenizer.
Now, specific Formulation Examples of the antitumour agent of the present invention will be mentioned.
70 mg of non-crystalline powder of the afore-mentioned Compound No. l was thoroughly mixed with 30 mg of lactose, and mixture was filled in capsules in an amount of 100 mg per capsule to obtain capsules for oral administration.
86.5 parts by weight of the non-crystalline powder of the afore-mentioned Compound No. 3 was uniformly mixed 20218~6 with l part by weight of glucose, 10 parts by weight of corn starch and 1.5 parts by weight of a 5% corn starch paste solution. The mixture was formed to granules by a wet method. Then, l part by weight of magnesium stearate was added thereto, and the mixture was tabletted by compression to obtain tablets for oral administration.
5 g of the afore-mentioned Compound No. 4 was dissolved in 5 ml of dimethyl acetamide, and 25 ml of coconut oil, 7 g of Pegnol HC-17 (registered trademark, hardened caster oil manufactured by Toho Kagaku) and 6 g of Pegnol HO-lOM (registered trademark, sucrose ester manufactured by Toho Kagaku) were added thereto to obtain an emulsion. To this emulsion, the same amount of sterilized distilled water was added, and the mixture was subjected to ultrasonic treatment for 20 to 30 second to obtain an emulsion.
The afore-mentioned Compound No. 26 was preliminarily pulverized to fine powder by a centrifugal pulverizer.
On the other hand, 5 parts by weight of polyoxyethylene (60) hardened castor oil, 0.2 part by weight of silicone and 0.3 part by weight of polyoxyethylene-polyoxypropylene block polymer were added to 79.5 parts by weight of a physiological saline to obtain an aqueous solution. To the aqueous solution, 10 parts by weight of the fine powder of the afore-mentioned Compound No. 3 was 202~89L~
added. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 80~ had a particle size of at most 2 ~um). Then, 5 parts by weight of a 2%
xanthane gum solution was added thereto to obtain an aqueous suspension.
40 parts by weight of the aore-mentioned Compound No. l was added to an aqueous solution containing 1.5 parts by weight of oxyethylated polyarylphenol phosphate and 0.2 part by weight of silicone dissolved in 53.3 parts by weight of a physiological saline. The mixturé
was wet pulverized by a sand mill by using glass beads (particles of which 90% had a particle size of at most 2 ~m). Then, 5 parts by weight of a 2% xanthane gum solution was added thereto to obtain an aqueous suspension.
The afore-mentioned Compound No. 4 was preliminarily pulverized to fine powder by a centrifugal pulverizer. 5 parts by weight of the fine powder of the Compound No. 4 was added to an aqueous solution obtained by dispersing and stirring 2 parts by weight of yolk phospholipid, 0.001 part by weight of a-tocopherol and 92.999 parts by weight of a physiological saline. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 80% had a particle size of at most 2 ~um) to obtain an aqueous suspension.
2021~6 The afore-mentioned Compound No. 3 was preliminarily pulverized to fine powder by a centrifugal pulverizer.
On the other hand, 5 parts by weight of polyoxyethylene (60) hardened castor oil was added to 60 parts by weight of a physiological saline to obtain an aqueous solution.
To the aqueous solution, 30 parts by weight of the fine powder of the Compound No. 3 was added. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 80% had a particle size of at most of 2 um). Then, 5 parts by weight of a 2% xanthane gum solution was added thereto to obtain an aqueous suspension.
10 parts by weight of the afore-mentioned Compound No. 1 was added to an aqueous solution containing 1.5 parts by weight of oxyethylated polyaryl phosphate, 0.2 part by weight of silicon and 0.3 part by weight of polyoxyethylene-polyoxypropylene block polymer dissolved in 81 parts by weight of a physiological saline. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 90% had a particle size of at most 2 ~m). Then, 7 parts by weight of a 2% xanthane gum solution was added thereto to obtain an aqueous suspension To l part by weight of the afore-mentioned Compound No. 2, 100 parts by weight of polyethylene~lycol # 900 (molecular weight: 380-420, manufactured by Nakarai Kagaku Yakuhin) was added and dissolved to obtain a homogeneous solution.
2.4 parts by weight of yolk phospholipid and 0.2 part by weight of the afore-mentioned Compound No. l were added to 40 parts by weight of medium chain triglyceride (ODO, tradename, manufactured by Nisshin Seiyu K.K.) and dissolved by means of a homomixer. Then, 57.4 parts by weight of distilled water was added thereto. The mixture was roughly emulsified by a homomixer and then emulsified by ultrasonic homogenizer to obtain a fatty emulsion having an average particle size of 1.0 ~m.
The afore-mentioned Compound No. 26 was preliminarily pulverized to fine powder by a centrifugal pulverizer.
On the other hand, 5 parts by weight of polyoxyethylene (60) hardened castor oil, 0.2 part by weight of silicone and 0.3 part by weight of polyoxyethylene-polyoxypropylene block polymer were added to 79.5 parts by weight of a physiological saline to obtain an aqueous solution. To the aqueous solution, 10 parts by weight of the fine powder of the afore-mentioned Compound No. 3 was 202~89L~
added. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 80~ had a particle size of at most 2 ~um). Then, 5 parts by weight of a 2%
xanthane gum solution was added thereto to obtain an aqueous suspension.
40 parts by weight of the aore-mentioned Compound No. l was added to an aqueous solution containing 1.5 parts by weight of oxyethylated polyarylphenol phosphate and 0.2 part by weight of silicone dissolved in 53.3 parts by weight of a physiological saline. The mixturé
was wet pulverized by a sand mill by using glass beads (particles of which 90% had a particle size of at most 2 ~m). Then, 5 parts by weight of a 2% xanthane gum solution was added thereto to obtain an aqueous suspension.
The afore-mentioned Compound No. 4 was preliminarily pulverized to fine powder by a centrifugal pulverizer. 5 parts by weight of the fine powder of the Compound No. 4 was added to an aqueous solution obtained by dispersing and stirring 2 parts by weight of yolk phospholipid, 0.001 part by weight of a-tocopherol and 92.999 parts by weight of a physiological saline. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 80% had a particle size of at most 2 ~um) to obtain an aqueous suspension.
2021~6 The afore-mentioned Compound No. 3 was preliminarily pulverized to fine powder by a centrifugal pulverizer.
On the other hand, 5 parts by weight of polyoxyethylene (60) hardened castor oil was added to 60 parts by weight of a physiological saline to obtain an aqueous solution.
To the aqueous solution, 30 parts by weight of the fine powder of the Compound No. 3 was added. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 80% had a particle size of at most of 2 um). Then, 5 parts by weight of a 2% xanthane gum solution was added thereto to obtain an aqueous suspension.
10 parts by weight of the afore-mentioned Compound No. 1 was added to an aqueous solution containing 1.5 parts by weight of oxyethylated polyaryl phosphate, 0.2 part by weight of silicon and 0.3 part by weight of polyoxyethylene-polyoxypropylene block polymer dissolved in 81 parts by weight of a physiological saline. The mixture was wet pulverized by a sand mill by using glass beads (particles of which 90% had a particle size of at most 2 ~m). Then, 7 parts by weight of a 2% xanthane gum solution was added thereto to obtain an aqueous suspension To l part by weight of the afore-mentioned Compound No. 2, 100 parts by weight of polyethylene~lycol # 900 (molecular weight: 380-420, manufactured by Nakarai Kagaku Yakuhin) was added and dissolved to obtain a homogeneous solution.
2.4 parts by weight of yolk phospholipid and 0.2 part by weight of the afore-mentioned Compound No. l were added to 40 parts by weight of medium chain triglyceride (ODO, tradename, manufactured by Nisshin Seiyu K.K.) and dissolved by means of a homomixer. Then, 57.4 parts by weight of distilled water was added thereto. The mixture was roughly emulsified by a homomixer and then emulsified by ultrasonic homogenizer to obtain a fatty emulsion having an average particle size of 1.0 ~m.
Claims (20)
1. A substituted benzoylurea compound of the formula (I):
(I) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2 and R3 is a hydrogen atom, an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt.
(I) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2 and R3 is a hydrogen atom, an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt.
2. The substituted benzoylurea compound or its salt according to the Claim 1, wherein the substituent of the substituted alkyl group, the substituted alkoxy group or the substituted alkylthio group in the definition of R4 is at least one member selected from the group consisting of a halogen atom, an alkoxy group, an alkylthio group, a cyano group, a thiocyanate group, an alkoxycarbonyl group, a carboxyl group and an alkylthiocarbonyl group, the substituent of the substituted alkyl group in the definition of R5 is a halogen atom, and the heterocyclic ring formed by R2 and R3 together with the adjacent nitrogen atom, is a morpholino group, an aziridinyl group, a pyrrolidinyl group, a piperidino group or a pyrrolyl group.
3. The substituted benzoylurea compound or its salt according to Claim 1, wherein the benzoylurea compound is of the formula (I'):
(I') wherein R1, R2, R3, R4 and R5 are as defined above.
(I') wherein R1, R2, R3, R4 and R5 are as defined above.
4. The substituted benzoylurea compound or its salt according to Claim 3, wherein R1 is a hydrogen atom.
5. The substituted benzoylurea compound or its salt according to Claim 3, wherein each of R2 and R3 is an alkyl group, or R2 and R3 form together with the adjacent nitrogen atom a heterocyclic ring.
6. The substituted benzoylurea compound or its salt according to Claim 3, wherein each of R2 and R3 is an alkyl group.
7. The substituted benzoylurea compound or its salt according to Claim 3, wherein R4 is a halogen atom or a substituted or unsubstituted alkyl group.
8. The substituted benzoylurea compound or its salt according to Claim 3, wherein R4 is a substituted or unsubstituted alkyl group.
9. The substituted benzoylurea compound or its salt according to Claim 3, wherein R5 is a halogen atom.
10. The substituted benzoylurea compound or its salt according to Claim 3, wherein the compound is N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea?hydrochloride, N-[4-(5-bromo-2-pyrimidinyloxy)-3-trifluoromethylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-chloro-2-pyrimidinyloxy)-3-trifluoromethylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea, N-[4-(5-bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea, or N-[4-(5-chloro-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(diethylamino)benzoyl]urea.
11. A process for producing a compound of the formula (I) (I) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2 and R3 is a hydrogen atom, an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2 and R3 may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (II):
(II) wherein R1, R4 and R5 are as defined above, and Hal is a halogen atom, with a compound of the formula (III):
(III) wherein R2 and R3 are as defined above.
(II) wherein R1, R4 and R5 are as defined above, and Hal is a halogen atom, with a compound of the formula (III):
(III) wherein R2 and R3 are as defined above.
12. A process for producing a compound of the formula (I-1):
(I-1) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2' and R3' is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2' and R3' may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, which comprises reacting a compound of the formula (IV):
(IV) wherein A1 is -NCO or -NH2, and R1, R2' and R3' are as defined above, with a compound of the formula (V):
(V) wherein A2 is -NH2 or -NCO, provided that when A1 is -NCO, A2 is -NH2, and when A1 is -NH2, A2 is -NCO, and R4 and R5 are as defined above.
(I-1) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2' and R3' is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), or R2' and R3' may form together with the adjacent nitrogen atom a heterocyclic ring, R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, which comprises reacting a compound of the formula (IV):
(IV) wherein A1 is -NCO or -NH2, and R1, R2' and R3' are as defined above, with a compound of the formula (V):
(V) wherein A2 is -NH2 or -NCO, provided that when A1 is -NCO, A2 is -NH2, and when A1 is -NH2, A2 is -NCO, and R4 and R5 are as defined above.
13. A process for producing a compound of the formula (I-2):
(I-2) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, R4 is a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (VI):
(VI) wherein R1, R4 and R5 are as defined above, and B1 is a phthaloyl group, with a hydrazine.
(I-2) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, R4 is a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (VI):
(VI) wherein R1, R4 and R5 are as defined above, and B1 is a phthaloyl group, with a hydrazine.
14. A process for producing a compound of the formula (I-3):
(I-3) wherein R1' is a hydrogen atom or a halogen atom, R4' is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group or a substituted or unsubstituted alkylthio group, and R5' is a halogen atom or a substituted or unsubstituted alkyl group, or its salt, which comprises reducing a compound of the formula (VII):
(VII) wherein R1' , R4' and R5' are as defined above.
(I-3) wherein R1' is a hydrogen atom or a halogen atom, R4' is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group or a substituted or unsubstituted alkylthio group, and R5' is a halogen atom or a substituted or unsubstituted alkyl group, or its salt, which comprises reducing a compound of the formula (VII):
(VII) wherein R1' , R4' and R5' are as defined above.
15. A process for producing a compound of the formula (IX):
(IX) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, R2" is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (I-2):
(I-2) wherein R1, R4 and R5 are as defined above, with a compound of the formula (VIII):
Hal - R2" (III) wherein R2" is as defined above.
(IX) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, R2" is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (I-2):
(I-2) wherein R1, R4 and R5 are as defined above, with a compound of the formula (VIII):
Hal - R2" (III) wherein R2" is as defined above.
16. A process for producing a compound of the formula (XI):
(XI) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2" and R3" is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (IX):
(IX) wherein R1, R2", R4 and R5 are as defined above, with a compound of the formula (X):
Hal - R3" (X) wherein R3" is as defined above, and Hal is a halogen atom.
(XI) wherein R1 is a hydrogen atom, a halogen atom or a nitro group, each of R2" and R3" is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), R4 is a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkylthio group or a nitro group, and R5 is a halogen atom, a nitro group or a substituted or unsubstituted alkyl group, or its salt, which comprises reacting a compound of the formula (IX):
(IX) wherein R1, R2", R4 and R5 are as defined above, with a compound of the formula (X):
Hal - R3" (X) wherein R3" is as defined above, and Hal is a halogen atom.
17. A composition for treating a cancer such as leukemia, melanoma, sarcoma or carcinoma in a mammal, which comprises a compound or its salt as defined in Claim 1 in an amount sufficient to exhibit a controlling activity against leukemia, melanoma, sarcoma or carcinoma and a pharmaceutically acceptable adjuvant.
18. A method of treating a cancer such as leukemia, melanoma, sarcoma or carcinoma in a mammal, which comprises administering a compound or its salt as defined in Claim 1 in an amount sufficient to exhibit a controlling activity against leukemia, melanoma, sarcoma or carcinoma.
19. A compound of the formula (XII):
(XII) wherein A1 is -NCO or -NH2, R1 is a hydrogen atom, a halogen atom or a nitro group, and each of R2''' and R3''' is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), provided that either R2''' or R3''' is -COR6 or -SO2R6.
(XII) wherein A1 is -NCO or -NH2, R1 is a hydrogen atom, a halogen atom or a nitro group, and each of R2''' and R3''' is an alkyl group, -COR6 (wherein R6 is an alkyl group or an alkoxy group) or -SO2R6 (wherein R6 is as defined above), provided that either R2''' or R3''' is -COR6 or -SO2R6.
20. The compound according to Claim 19, wherein A1 is -NH2.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19588389 | 1989-07-28 | ||
| JP195883/1989 | 1989-07-28 | ||
| JP322094/1989 | 1989-12-12 | ||
| JP32209489 | 1989-12-12 | ||
| JP11352990 | 1990-04-27 | ||
| JP113529/1990 | 1990-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2021846A1 true CA2021846A1 (en) | 1991-01-29 |
Family
ID=27312527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002021846A Abandoned CA2021846A1 (en) | 1989-07-28 | 1990-07-24 | Substituted benzoylurea compounds or their salts, processes for their production and antitumour compositions containing them |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5102884A (en) |
| EP (1) | EP0413977A3 (en) |
| KR (1) | KR910002809A (en) |
| AU (1) | AU623030B2 (en) |
| CA (1) | CA2021846A1 (en) |
| HU (1) | HU207854B (en) |
| NZ (1) | NZ234551A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05247001A (en) * | 1991-12-05 | 1993-09-24 | Ishihara Sangyo Kaisha Ltd | Substituted benzoylurea derivative or its salt, their production and anticancer agent comprising the same |
| KR950026862A (en) * | 1994-03-15 | 1995-10-16 | 강박광 | Benzoyl urea derivatives |
| CA3006799A1 (en) * | 2015-12-01 | 2017-06-08 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Htert modulators and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ212208A (en) * | 1984-06-15 | 1988-04-29 | Ishihara Sangyo Kaisha | N-benzoyl-n'-pyrimidinyloxyphenyl ureas and pharmaceutical compositions |
| JPS6193163A (en) * | 1984-10-12 | 1986-05-12 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation and carcinostatic agent containing same |
| US4727077A (en) * | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
| AU601145B2 (en) * | 1985-03-01 | 1990-09-06 | Duphar International Research B.V. | Benzoyl urea derivatives having anti-tumor activity |
| AU594098B2 (en) * | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
| JPH029855A (en) * | 1988-03-31 | 1990-01-12 | Ishihara Sangyo Kaisha Ltd | Substituted benzene derivative, production thereof and anti-cancer composition containing the same derivative |
-
1990
- 1990-07-17 NZ NZ234551A patent/NZ234551A/en unknown
- 1990-07-19 US US07/554,449 patent/US5102884A/en not_active Expired - Lifetime
- 1990-07-23 EP EP19900114085 patent/EP0413977A3/en not_active Withdrawn
- 1990-07-24 CA CA002021846A patent/CA2021846A1/en not_active Abandoned
- 1990-07-26 AU AU59832/90A patent/AU623030B2/en not_active Ceased
- 1990-07-27 HU HU904654A patent/HU207854B/en not_active IP Right Cessation
- 1990-07-27 KR KR1019900011451A patent/KR910002809A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU5983290A (en) | 1991-01-31 |
| AU623030B2 (en) | 1992-04-30 |
| NZ234551A (en) | 1991-10-25 |
| US5102884A (en) | 1992-04-07 |
| HU207854B (en) | 1993-06-28 |
| KR910002809A (en) | 1991-02-26 |
| HUT54355A (en) | 1991-02-28 |
| EP0413977A2 (en) | 1991-02-27 |
| EP0413977A3 (en) | 1991-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0226104B1 (en) | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation | |
| US4727077A (en) | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them | |
| JP4806508B2 (en) | Androgen receptor suppressor for the treatment or diagnosis of prostate cancer, alopecia or other hyperandrogen syndrome | |
| JP2575183B2 (en) | Anti-hyperlipidemic and anti-atherosclerotic urea and carbamate compounds | |
| KR870000741B1 (en) | Preparation of benzenesulfonamide derivatives | |
| KR20160066014A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| CN1880306A (en) | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | |
| CA2412941A1 (en) | Piperidine compounds for use as ccr-3 inhibitors | |
| TW213445B (en) | ||
| CZ20012141A3 (en) | Use of androgen receptor inhibitors | |
| US4845093A (en) | N-benzoyl-N'-pyridazinyloxyphenyl urea compounds, and antitumorous compositions containing them, and process for their preparation | |
| EP0178572A2 (en) | N-Benzoyl-N'-(3-Nitrophenyl) urea compounds, and antitumorous compositions containing them, and process for their preparation | |
| JPS6210057A (en) | Drug | |
| CA2021846A1 (en) | Substituted benzoylurea compounds or their salts, processes for their production and antitumour compositions containing them | |
| JPS6259264A (en) | 5-pyrimidinecarboxamides, manufacture and medicinal composition | |
| US4987135A (en) | Substituted benzene derivatives, processes for their production and antitumor compositions containing them | |
| EP0164694B1 (en) | N-benzoyl-n'-pyrimidinyloxyphenyl urea compounds, and antitumorous compositions containing them, and process for their preparation | |
| RU2194046C2 (en) | Novel nitromethylketones, method of their synthesis and compositions comprising thereof | |
| JPH10212235A (en) | Antitumor medicine | |
| JPH01268670A (en) | 2-nitrobenzoylurea compound, production thereof and anti-cancer drug containing said compound | |
| PL163394B1 (en) | Method of obtaining substituted derivatives of benzoilurea or their salts | |
| JPS61205257A (en) | Benzoylurea compound, production thereof, and anticancer drug containing same | |
| JPH05294923A (en) | Antitumor composition and treatment with the same | |
| JPH0429979A (en) | Substituted benzoylurea compound or its salt, preparation thereof and anticancer drug containing the same | |
| CA1266474A (en) | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |